USAID

World TB Day event: Innovating to End TB

USAID and TB Alliance will host an event, Innovating to End TB on 14 March 2017, 12:00 PM – 6:30 PM EDT in Washington, D.C., United States.

Read More →

Economic cost of non-adherence to TB medicines resulting from stock-outs and loss to follow-up in the Philippines

One of the key elements of successful tuberculosis (TB) control programs is adherence to treatment, and this is a cornerstone of most international and national policies and guidelines. Non-adherence is often due to patient-related factors, but can also be a result of provider issues, such as stock-outs of TB medicines. Non-adherence results in increases in length and severity of illness, deaths, disease transmission, and drug resistance. These have economic consequences in terms of costs and loss of income for patients and their families and also costs to the health system.

Read More →

SURVEY: DR-TB patients & providers

Only half of patients who start treatment for drug-resistant TB (DR-TB) finish it successfully. The reasons are many, and often are related to non-medical challenges. USAID is working with patients, their supporters and frontline providers, to develop a patient-centered care package.

Read More →

USAID 2015 report on foreign assistance for TB

The U.S. Agency for International Development (USAID) released an annual report illustrating the USAID's contribution during Fiscal Year 2015 to international TB programming. USAID supported screening, diagnosis and treatment services for people affected by TB and multidrug-resistant TB.

Read More →

U.S. agencies release progress report on National Action Plan for Combating MDR-TB

On 22 December 2015 the White House officially released a plan to address multidrug-resistant tuberculosis (MDR-TB) domestically and internationally and to advance research on this critical public health issue through a National Action Plan for Combating Multidrug-Resistant Tuberculosis.

Read More →

Kyrgyz Republic gets new tools to fight TB

USAID launched a patient-centered outpatient approach to TB care in the Kyrgyz Republic’s most populous and TB-affected region.

Read More →

Tajikistan: U.S. Government engages civil society to prevent tuberculosis

Dushanbe, Tajikistan, February 26, 2016 – The United States Agency for International Development (USAID) Tuberculosis Control Program conducted a five-day workshop on the World Health Organization’s (WHO) ENGAGE-TB approach to integrate community-based tuberculosis (TB) activities into the work of non-governmental and civil society organizations. The training promotes community-based TB activities, expansion of TB services through civil society, and integration with other development sectors. As a result of the training, non-governmental organizations and civil society organizations will be able to better implement this approach in collaboration with each other and with the National TB Control Program. Upon conclusion of the training, participants will form a working group to develop the new, national Community Engagement Plan 2016-2020 for Tajikistan, which will replace the former National Advocacy, Communication, and Social Mobilization Plan 2010-2015.

Read More →

Prominent healthcare companies partner with USAID to combat drug-resistant tuberculosis

WASHINGTON, D.C., January 7, 2016 - The U.S. Agency for International Development (USAID) announced two new partnerships today to add resources and cutting-edge technologies to fight drug-resistant tuberculosis (TB). Janssen, the pharmaceutical arm of Johnson & Johnson, announced a $15-20 million pledge as part of a new partnership with USAID to combat multidrug-resistant tuberculosis (MDR-TB). USAID will also partner with Cepheid, a maker of molecular systems and tests, to speed diagnosis of MDR-TB through increased access to rapid, accurate diagnostic tools.

Read More →

USAID to reach patients in more than 100 countries with life-saving medicine for drug-resistant tuberculosis

Patients in Georgia suffering from deadly strains of multidrug-resistant tuberculosis (MDR-TB) will soon have access to potentially life-saving medication thanks to a collaboration between the U.S. Agency for International Development (USAID) and Janssen. Nearly 200 patients in Georgia will begin receiving the tuberculosis drug, SIRTURO® (bedaquiline), as part of their treatment program for MDR-TB. Georgia is classified as a high MDR-TB burden country with 48 percent of known TB cases being identified as multidrug-resistant.

Read More →

USAID releases report to Congress on U.S. Government international foreign assistance for tuberculosis

Today, the U.S. Agency for International Development (USAID) released its annual report to Congress on U.S. Government (USG) international foreign assistance for tuberculosis (TB) control.

Read More →

Page 1 of 1 · Total posts: 10

1